# CMR-T1 en ECV voorspellen MACE en hartfalen bij hypertrofische cardiomyopathie

*geplaatst 2026-11-22 · Hartfalen · European journal of radiology open · doi 10.1016/j.ejro.2026.100822 · https://hartvaat.nl/2026/12/01/cmr-t1-en-ecv-voorspellen-mace-en-hartfalen-bij-hypertrofische-cardiomyopathie/*

Een meta-analyse van acht cohortonderzoeken (n=2539) toont aan dat native T1-mapping en extracellulaire volume (ECV) op cardiovasculaire MRI significant samenhangen met MACE bij hypertrofische cardiomyopathie (HR respectievelijk 1,27 en 1,10 per eenheidstoename). ECV is bovendien geassocieerd met hartfalen-gerelateerde uitkomsten (HR 1,10), terwijl de voorspellende waarde voor plotselinge hartdood onzeker blijft door heterogeniteit. Voor cardiologen biedt dit bewijs voor de toegevoegde waarde van deze MRI-biomarkers in de risicostratificatie en klinische besluitvorming bij HCM.

## English: Prognostic value of native T1 mapping and extracellular volume fraction in hypertrophic cardiomyopathy: A systematic review and meta-analysis.

A meta-analysis of eight longitudinal cohorts (n=2539) demonstrates that elevated native T1 values and higher extracellular volume (ECV) on cardiac MRI are significantly associated with major adverse cardiovascular events in hypertrophic cardiomyopathy (HR 1.27 and 1.10 per unit increase, respectively). ECV also independently predicts heart failure-related outcomes (HR 1.10), whereas its association with sudden cardiac death requires further validation due to substantial heterogeneity. These findings support the routine integration of T1 mapping and ECV into risk stratification strategies for HCM patients.

## Abstract (original, from the publication)

BACKGROUND: Accurate risk stratification in hypertrophic cardiomyopathy (HCM) remains challenging, and the prognostic significance of cardiovascular magnetic resonance-derived native T1 mapping and extracellular volume fraction (ECV) remains uncertain. AIMS: To systematically evaluate the prognostic value of native T1 mapping and ECV in HCM patients. METHODS: PubMed, Embase, MEDLINE, and the Cochrane Library were searched from inception to February 6, 2026. Eligible studies assessed native T1 and/or ECV for prognosis in HCM. Baseline values, mean differences, and hazard ratios (HRs) were synthesized using random-effects models. Effect estimates were standardized as HRs per 30-ms increase in native T1 and per 1% increase in ECV. RESULTS: Eight longitudinal cohort studies involving 2539 HCM patients were included. Elevated native T1 was significantly associated with an increased risk of major adverse cardiovascular events (MACE) (HR=1.27, 95% CI: 1.12-1.44, P < 0.001), as was higher ECV (HR=1.10, 95% CI: 1.07-1.14, P < 0.001). For sudden cardiac death-related outcomes, the association with native T1 was not significant, whereas elevated ECV was associated with an increased risk (HR=1.14, 95% CI: 1.01-1.28, P = 0.04), although substantial heterogeneity was observed and sensitivity analysis indicated limited robustness (HR=1.05, 95% CI: 0.97-1.14, P = 0.21). For heart failure-related outcomes, only ECV was associated with risk (HR=1.10, 95% CI: 1.05-1.15; P < 0.001). CONCLUSIONS: Native T1 and ECV were associated with MACE risk in HCM, and ECV was additionally associated with heart failure-related outcomes. Their value for sudden cardiac death-related risk prediction requires further validation. PROSPERO REGISTRATION NUMBER: CRD420261406609.

Auteurs: Qi Wang, Wenqi Liu, Jingjing Shi, Wanzhen Li, Jie Lin, Zhenchang Wang, Yiyuan Gao

---
Bron: European journal of radiology open, https://doi.org/10.1016/j.ejro.2026.100822. Bijgewerkt 2026-11-15T02:40:27Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.
